First-ever rapid-acting insulin. This approval extends to a 3-milliliter single-patient-use prefilled pen and a 10-milliliter ...

Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.

The U.S. Food and Drug Administration (FDA) recently approved Merilog (insulin-aspart-szjj) as the first rapid-acting insulin ...

The US Food and Drug Administration (FDA) has approved Sanofi’s Merilog (insulin-aspart-szjj), a biosimilar to Novolog ...

According to the FDA, the medication quickly helps to lower mealtime blood sugar spikes to improve control of blood sugar in ...

The FDA approved insulin-aspart-szjj (Merilog) as the first rapid-acting insulin biosimilar product to treat adults and ...

In an awake individual, mild-to-moderate nocturnal hypoglycemia is easily corrected by ingesting a snack containing approximately 5 g of fast-acting carbohydrate ... the basal insulin, a bedtime ...

Use of the long-acting insulin analogs glargine and detemir does not reduce the risk of diabetic ketoacidosis in children and adolescents with type 1 diabetes mellitus (T1DM), compared with the ...

SILVER SPRING, Md., Feb. 14, 2025 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Merilog (insulin-aspart-szjj) as biosimilar to Novolog (insulin aspart) for the improvement ...

Merilog is the third insulin biosimilar product approved by the FDA and joins the two long-acting insulin biosimilar products approved in 2021 by the FDA. Approval of biosimilar products can ...